Meeting
2013 ASCO Annual Meeting
Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreas cancer (BRPC).
Authors
J Bart Rose
Virginia Mason Medical Center, Seattle, WA
J Bart Rose , Flavio G. Rocha , Bruce S. Lin , Adnan Alseidi , Thomas A. Biehl , Ravi Moonka , John A. Ryan , L. William Traverso , Scott Helton , Vincent J. Picozzi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4043)
DOI
10.1200/jco.2013.31.15_suppl.4043
Abstract #
4043
Poster Bd #
16E
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Survival outcomes of patients with resectable pancreatic cancer treated with upfront surgery versus neoadjuvant chemotherapy: A retrospective tertiary care center experience.
First Author: Fang Liu
Poster
2019 ASCO Annual Meeting
The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/JSAP-05).
First Author: Sohei Satoi
Poster
2019 Gastrointestinal Cancers Symposium
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).
First Author: Michiaki Unno
Poster
2019 Gastrointestinal Cancers Symposium
Neoadjuvant multimodal treatment of borderline resectable (BRPC) and locally advanced unresectable pancreatic cancer (LAPC) in Mexico.
First Author: Vanessa Rosas Camargo